Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Treatment crawled date : 2022 - 11 - 01 save search
Cocrystal Pharma Granted European Patent Covering Oral Antiviral Candidate CC-42344 in Combination with Another Antiviral Agent for the Treatment of Influenza
Published: 2022-11-01 (Crawled : 22:00) - biospace.com/
COCP | $1.5299 -1.39% 9.7K
|
Health Technology
|
| O: 4.03%
H: 0.78%
C: -4.65%
cc-4234 treatment pharma patent candidate antiviral granted influenza cc-42344
Eloxx Pharmaceuticals Announces Opening of Clinical Trial Sites for Phase 2 Study of ELX-02 for the Treatment of Alport SyndromeTrial sites now open in Australia and the United Kingdom
Published: 2022-11-01 (Crawled : 22:00) - biospace.com/
ELOX | $0.801 -51.57% 93K
|
Health Technology
|
| O: 7.0%
H: 2.4%
C: -3.76%
elx-02 treatment pharmaceuticals australia trial study
Gilead to Present Data Across Viral Hepatitis and Liver Fibrosis at The Liver Meeting® 2022, Reinforcing Gilead as a Leader in Addressing Treatment Needs for People Living With Liver Disease
Published: 2022-11-01 (Crawled : 16:00) - biospace.com/
GILD | $66.95 0.29% 0.28% 5.6M
|
Health Technology
|
| O: -0.25%
H: 1.65%
C: 1.38%
meeting treatment hepatitis fibrosis liver disease living
Cingulate Completes Fed/Fast Study Assessing Food Effect with CTx-1301, Lead Candidate for Treatment of ADHD
Published: 2022-11-01 (Crawled : 13:00) - globenewswire.com
CING | $0.89 1.24% 1.22% 73K
|
|
| O: 2.78%
H: 2.7%
C: -1.8%
treatment candidate adhd food study
Monte Rosa Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating MRT-2359, a GSPT1-directed Molecular Glue Degrader, for Treatment of MYC-driven Tumors
Published: 2022-11-01 (Crawled : 12:00) - biospace.com/
GLUE | $5.55 -5.13% -5.41% 120K
|
Professional, Scientific, and T...
|
| O: 1.41%
H: 0.86%
C: -3.22%
mrt-2359 treatment rosa trial therapeutics tumors molecular
AngioDynamics Announces First Patient Enrolled in APEX-AV Study Assessing AlphaVac F1885 PE System in Treatment of Pulmonary Embolism
Published: 2022-10-31 (Crawled : 00:00) - biospace.com/
ANGO | $6.27 0.16% 0.16% 340K
|
Health Technology
|
| O: -0.59%
H: 5.74%
C: 5.07%
treatment system study
Gainers vs Losers
| 75% | 25% |
Top 10 Gainers
MTTR | News M | $4.78 174.71% 63.6% 72M
|
AGBA | $2.565 105.2% 51.27% 200M
|
Finance
MLEC | $2.44 74.29% 42.62% 78M
|
n/a
EDBL | News | $6.28 67.02% 40.13% 16M
|
ATGL | $2.91 48.81% 32.8% 180K
|
ZAPP | $0.2175 47.16% 32.05% 16M
|
n/a
ONFO | $0.6075 38.38% 27.74% 7.3M
|
n/a
VIVK | $1.48 38.32% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.8M
|
SDIG A | $3.635 35.13% 26.0% 1M
|
Your saved searches
Save your searches and get alerts when important news are released.